Search for a trial | Research with human participants

1 results

A Phase 1/1b Open-Label, Multicenter, to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN 2787 in Participants with BRAF and/or NRAS Mutation positive Solid Tumors

Approved WMORecruitment stopped

Part A1(KIN-2787 Monotherapy Escalation):Determine safety and tolerability of PO administration of Kin-2787 including DLT in participants with BRAFmutation-positive advanced or metastatic solid tumors or melanoma harboring NRAS-mutation. Identify…